肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2010年
8期
534-536
,共3页
王顺兰%陈明远%胡伟汉%苏勇%林焕新%阮岩%邱宝珊
王順蘭%陳明遠%鬍偉漢%囌勇%林煥新%阮巖%邱寶珊
왕순란%진명원%호위한%소용%림환신%원암%구보산
鼻咽肿瘤%肿瘤,继发原发性%舌肿瘤
鼻嚥腫瘤%腫瘤,繼髮原髮性%舌腫瘤
비인종류%종류,계발원발성%설종류
Nasopharyngeal neoplasms%Neoplasms,second primary%Tongue neoplasms
目的 探讨鼻咽癌放疗后第二原发舌鳞癌的临床特点、有效的治疗手段、生存情况和影响预后的因素.方法 回顾性分析35例鼻咽癌放疗后第二原发舌鳞癌患者的临床和随访资料,应用Kaplan-Meier法及Log-Rank检验、COX回归模型等对本组病例资料进行统计分析.结果 35例患者总的3、5年生存率分别为55%、47%,淋巴结转移率为5.71%;单因素分析提示性别(χ2=8.89,P:0.00)、T分级(χ2=5.58,P=0.02)、临床分期(χ2=8.51,P=0.04)、治疗方法(χ2=29.37,P=0.00)是影响预后的重要因素;多因素分析显示治疗方法(P=0.00)、T分级(P=0.03)是与预后有关的重要独立因素;手术治疗组较非手术治疗组预后好,差异有统计学意义(P<0.05);男性患者发生第二原发舌鳞癌的风险较女性患者高;第二原发舌鳞癌随鼻咽癌放疗后时间的延长发病率升高.结论 鼻咽癌放疗后第二原发舌鳞癌淋巴转移率较低;治疗方法和T分期是影响预后的独立凶素;鼻咽癌放疗后需长期随访,早期诊断第二原发舌鳞癌,并给予手术或包含手术的综合治疗,以取得好的疗效.
目的 探討鼻嚥癌放療後第二原髮舌鱗癌的臨床特點、有效的治療手段、生存情況和影響預後的因素.方法 迴顧性分析35例鼻嚥癌放療後第二原髮舌鱗癌患者的臨床和隨訪資料,應用Kaplan-Meier法及Log-Rank檢驗、COX迴歸模型等對本組病例資料進行統計分析.結果 35例患者總的3、5年生存率分彆為55%、47%,淋巴結轉移率為5.71%;單因素分析提示性彆(χ2=8.89,P:0.00)、T分級(χ2=5.58,P=0.02)、臨床分期(χ2=8.51,P=0.04)、治療方法(χ2=29.37,P=0.00)是影響預後的重要因素;多因素分析顯示治療方法(P=0.00)、T分級(P=0.03)是與預後有關的重要獨立因素;手術治療組較非手術治療組預後好,差異有統計學意義(P<0.05);男性患者髮生第二原髮舌鱗癌的風險較女性患者高;第二原髮舌鱗癌隨鼻嚥癌放療後時間的延長髮病率升高.結論 鼻嚥癌放療後第二原髮舌鱗癌淋巴轉移率較低;治療方法和T分期是影響預後的獨立兇素;鼻嚥癌放療後需長期隨訪,早期診斷第二原髮舌鱗癌,併給予手術或包含手術的綜閤治療,以取得好的療效.
목적 탐토비인암방료후제이원발설린암적림상특점、유효적치료수단、생존정황화영향예후적인소.방법 회고성분석35례비인암방료후제이원발설린암환자적림상화수방자료,응용Kaplan-Meier법급Log-Rank검험、COX회귀모형등대본조병례자료진행통계분석.결과 35례환자총적3、5년생존솔분별위55%、47%,림파결전이솔위5.71%;단인소분석제시성별(χ2=8.89,P:0.00)、T분급(χ2=5.58,P=0.02)、림상분기(χ2=8.51,P=0.04)、치료방법(χ2=29.37,P=0.00)시영향예후적중요인소;다인소분석현시치료방법(P=0.00)、T분급(P=0.03)시여예후유관적중요독립인소;수술치료조교비수술치료조예후호,차이유통계학의의(P<0.05);남성환자발생제이원발설린암적풍험교녀성환자고;제이원발설린암수비인암방료후시간적연장발병솔승고.결론 비인암방료후제이원발설린암림파전이솔교저;치료방법화T분기시영향예후적독립흉소;비인암방료후수장기수방,조기진단제이원발설린암,병급여수술혹포함수술적종합치료,이취득호적료효.
Objective To investigate the clinical features, effective treatment, survival and prognostic factors of second primary tongue squamous cell carcinoma (SPTSCC) after nasopharyngeal carcinoma (NPC) radiotherapy. Methods The clinical data of 35 cases with SPTSCC after NPC radiotherapy were analyzed retrospectively. Kaplan-Meier method, Log-Rank test and COX proportional hazard mode was performed for statistical analysis. Results 3-year and 5-year overall survival rates were 55 % and 47 %, respectively, lymph node metastasis rate was 5.71 %. Univariate analysis indicated that gender (χ2 = 8.89, P = 0.00), T classification (χ2= 5.58, P= 0.02), clinical stage (χ2 = 8.51, P= 0.04) and treatment methods (χ2 = 29.37, P = 0.00) were important factors of prognosis. Multivariate analysis showed that treatment methods (P = 0.00) and T classification (P = 0.03) were independent prognostic factors. Operative treatment group had better prognosis than the non-operative treatment group, the difference was statistically significant (P <0.05), male patients in the risk of SPTSCC was higher than the female patients, and the incidence of SPTSCC was increased along with extension of the time after NPC radiotherapy. Conclusion The rate of the lymph node metastasis is lower for SPTSCC after NPC radiotherapy and treatment patterns and T stage are independent prognostic factors. Long-term follow-up after NPC radiotherapy is necessary to the early diagnosis of SPTSCC, so that to give surgery or combined therapy with surgery in order to achieve a good effect.